Cholangitis Market - Forecast(2024 - 2030)

Cholangitis Market size is forecast to reach $332.01Million by 2025, growing at a CAGR of 4.8% during the forecast period 2020-2025. Growing prevalence of cholangitis and bile duct disorders among the geriatric population are major factors driving the growth of the market. Increasing health awareness among people, state- funded policies for treatment of cholangitis and adoption of advanced treatment methods like intravenous therapy in major nations is likely to further enhance the overall Cholangitis Market demand during the forecast period 2020-2025. Cholangitis Market Industry Analysis is based on disease type, application, and geography.

Acute Cholangitis held the largest share in the disease type segment of Cholangitis Market in 2019 and is estimated to grow at a CAGR of 3.5% during the forecast period 2020-2025. Acute cholangitis is usually caused by bacteria ascending from its junction with the duodenum. This causes inflammation of the bile duct. Increasing cases of bladder stones and bacterial infection further lead to frequent cases of the disease. Primary Sclerosing Cholangitis (PSC) held the second- largest share in the market, owing to its growing prevalence and far more mortality rate. PSC is one of the leading reasons people require a liver transplant in the U.S. However, it is estimated that Recurrent pyogenic cholangitis (RPC) will be the fastest- growing segment and will register the highest CAGR during the forecast period, owing to growing cases of intrahepatic pigmented stones and recurrent attacks of cholangitis.

Clinical practices hold the major share in the application segment of Cholangitis Market in 2019. Rising demand for quick and efficient treatments are attributed to the market growth of this segment. Research area is projected to witness steady growth in the forecast period, owing to increasing need of treatment in intense cholangitis diseases like chronic cholangitis. Chronic cholangitis may be an autoimmune disease in which the body’s own immune system mistakenly attacking the bile ducts, causing inflammation. Over time, this inflammation can trigger scars or the growth of hard tissue inside the bile ducts.

North America dominates the Cholangitis Market in 2019, with a share of more than 43%, followed by Europe. Increasing geriatric population along with increasing healthcare awareness and the good state funded regulations have fuelled the Cholangitis market growth in this region.

However, Asia Pacific is estimated to grow at a higher CAGR during the forecast period 2020-2025. This is owing to the developing countries like China and India anticipation to see reasonable cholangitis cases in face of gallstones disorders and pancreatic cancer, which are further set to drive the demand for gallbladder treatment.

Cholangitis occurs with a wide range of severity, from low fever to severe sepsis and shock with frank pus within the biliary tree, which is also known as acute suppurative cholangitis. The reported mortality rate for acute suppurative cholangitis was as high as 88% in 2018. Mortality rate ranges from 5-10%, with a higher mortality rate in patients who require emergency decompression or surgery. As such, people tend to consult health departments on getting the preliminary symptoms. These are forecast to drive the Cholangitis Market trends in the forecast period.

Cholangitis occurs if a person has a history of gallstones, sclerosing cholangitis, HIV (human immunodeficiency virus) or an abnormally narrow bile duct, which can be congenital. In most cases, it is usually found that the unhealthy lifestyle and consumption of bad food coupled with pollution increases the cases of cholangitis case thus set to impact the market growth.

Increasing treatment expenses in recent times have resulted in fewer treatments, owing to the inability of middle class population to avail them. Growing treatment costs and taxes may cause less availing of the treatment and consequent hampering of market growth during the forecast period.

Product launches, mergers and acquisitions, joint ventures and R&D activities are key strategies adopted by players in the Cholangitis Market. In 2019, Cholangitis Market share is consolidated by the top players present in the market. Cholangitis Market top 10 companies are Gilead Sciences, RiemserArzneimittel AG, Bayer AG, Zambon Company S.p.A., Taiho Pharmaceutical Co., Ltd., Mayo Clinic, NGM Biopharmaceuticals, Intercept Pharmaceuticals, Inc., HighTide Therapeutics Inc. and Acorda Therapeutics, Inc. among others.